Monthly Archives: June 2018

http://www.lslog.com/car-t-race-heads-to-europe-as-gilead-novartis-drugs-score-chmp-backing/CAR-T race heads to Europe as Gilead, Novartis drugs score CHMP backing

CAR-T race heads to Europe as Gilead, Novartis drugs score CHMP backing

CAR-T race heads to Europe as Gilead, Novartis drugs score CHMP backing Gilead and Novartis CAR-T cancer drugs Yescarta and Kymriah won an EMA committee backing for marketing approval. Source: […]

http://www.lslog.com/englands-cost-watchdogs-shoot-down-roches-ocrevus-the-only-approved-therapy-for-ppms/England's cost watchdogs shoot down Roche's Ocrevus, the only approved therapy for PPMS

England's cost watchdogs shoot down Roche's Ocrevus, the only approved therapy for PPMS

England’s cost watchdogs shoot down Roche’s Ocrevus, the only approved therapy for PPMS Roche’s Ocrevus may be the only approved treatment for primary progressive multiple sclerosis, a tough-to-treat form of […]

http://www.lslog.com/after-nearly-3-years-fda-lifts-hold-on-aptose-cancer-drug/After nearly 3 years, FDA lifts hold on Aptose cancer drug

After nearly 3 years, FDA lifts hold on Aptose cancer drug

After nearly 3 years, FDA lifts hold on Aptose cancer drug The FDA has lifted a clinical hold on Aptose Biosciences’ APTO-253 almost three years after it stopped the blood […]

http://www.lslog.com/gemphire-sparkles-on-third-trial-win-for-lead-drug-gemcabene/Gemphire sparkles on third trial win for lead drug gemcabene

Gemphire sparkles on third trial win for lead drug gemcabene

Gemphire sparkles on third trial win for lead drug gemcabene Shares in Gemphire Therapeutics more than doubled after its lead drug gemcabene aced a midstage trial in patients with high […]

http://www.lslog.com/amazon-gets-a-drug-distribution-beachhead-in-pillpack-buy/Amazon gets a drug distribution beachhead in PillPack buy

Amazon gets a drug distribution beachhead in PillPack buy

Amazon gets a drug distribution beachhead in PillPack buy Amazon purchased small pharmacy startup PillPack on Thursday, spooking investors in leading drug distribution and pharmacy giants. Source: Fierce Pharma Amazon […]

http://www.lslog.com/newly-discovered-protein-could-boost-hunt-for-drugs-to-treat-sepsis-and-other-inflammatory-diseases/Newly discovered protein could boost hunt for drugs to treat sepsis and other inflammatory diseases

Newly discovered protein could boost hunt for drugs to treat sepsis and other inflammatory diseases

Newly discovered protein could boost hunt for drugs to treat sepsis and other inflammatory diseases The life-threatening disease sepsis is just one of several illnesses marked by overblown inflammation. Scientists […]

http://www.lslog.com/sanofi-advent-finally-shake-hands-on-2-2b-european-generics-sale/Sanofi, Advent finally shake hands on $2.2B European generics sale

Sanofi, Advent finally shake hands on $2.2B European generics sale

Sanofi, Advent finally shake hands on .2B European generics sale It’s official: Sanofi is finally ready to unload its European generics business. More than two months after disclosing that they […]

http://www.lslog.com/newcomer-appello-raises-10-5m-for-new-vanderbilt-parkinsons-drug/Newcomer Appello raises $10.5M for new Vanderbilt Parkinson’s drug

Newcomer Appello raises $10.5M for new Vanderbilt Parkinson’s drug

Newcomer Appello raises .5M for new Vanderbilt Parkinson’s drug Appello Pharmaceuticals raised $10.5 million to fund development of a new treatment for Parkinson’s disease licensed from Vanderbilt University’s Center for […]

http://www.lslog.com/ready-to-challenge-novartis-and-roche-array-scores-fda-nod-for-melanoma-combo/Ready to challenge Novartis and Roche, Array scores FDA nod for melanoma combo

Ready to challenge Novartis and Roche, Array scores FDA nod for melanoma combo

Ready to challenge Novartis and Roche, Array scores FDA nod for melanoma combo Array will challenge pharma giants Novartis and Roche in its rollout of new cancer drugs Braftovi and […]

http://www.lslog.com/rare-disease-specialist-spectrum-eyes-potential-2b-plus-sale-bloomberg/Rare disease specialist Spectrum eyes potential $2B-plus sale: Bloomberg

Rare disease specialist Spectrum eyes potential $2B-plus sale: Bloomberg

Rare disease specialist Spectrum eyes potential B-plus sale: Bloomberg Biopharma M&A has picked up this year with deals worth more than $34 billion so far, not counting Takeda’s $62 billion […]